Skip to product information
1 of 1

FITC Mouse Anti-Human CD314 (NKG2D) Antibody (S-4154)

FITC Mouse Anti-Human CD314 (NKG2D) Antibody (S-4154)

Catalog Number: S0B8828 Application: FCM Reactivity: Human Conjugation: FITC Brand: Starter
Price:
Regular price $180 USD
Regular price Sale price $180 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Mouse
Antigen CD314 (NKG2D)
Synonyms NKG2-D type II integral membrane protein; Killer cell lectin-like receptor subfamily K member 1; NK cell receptor D; NKG2-D-activating NK receptor; D12S2489E; KLRK1
Location Cell membrane
Accession P26718
Clone Number S-4154
Antibody Type Mouse mAb
Isotype IgG1,k
Application FCM
Reactivity Hu
Positive Sample Human PBMC
Purification Protein G
Concentration 0.2 mg/ml
Conjugation FITC
Physical Appearance Liquid
Storage Buffer

PBS, 1% BSA, 0.3% Proclin 300

Stability & Storage

12 months from date of receipt / reconstitution, 2 to 8 °C as supplied

Dilution


application dilution species
FCM 5μl per million cells in 100μl volume Hu

Background

CD314, also known as NKG2D (Natural Killer Group 2D), is a type II transmembrane glycoprotein and a member of the C-type lectin-like receptor family that serves as an activating receptor expressed on the surface of natural killer (NK) cells, CD8+ T cells, γδ T cells, and NKT cells. It functions as a homodimeric receptor that recognizes stress-induced ligands, including MICA, MICB, and ULBP1-6 (UL16-binding proteins) in humans, which are upregulated on infected, transformed, or damaged cells due to cellular stress, DNA damage, or viral infection. Upon ligand engagement, NKG2D associates with the adaptor protein DAP10 (DNAX-activating protein of 10 kDa) through a charged transmembrane interaction, triggering phosphoinositide 3-kinase (PI3K)-dependent signaling pathways that promote cytotoxicity, cytokine production, and enhanced immune surveillance. Unlike many other NK cell receptors, NKG2D signaling is not inhibited by self-MHC class I molecules, making it a critical mechanism for distinguishing healthy cells from aberrant cells in the context of cancer immunosurveillance, viral defense, and autoimmune regulation. Dysregulation of the NKG2D-ligand axis has been implicated in various pathological conditions, including tumor immune evasion through ligand shedding or downregulation, as well as autoimmune diseases such as rheumatoid arthritis and type 1 diabetes, highlighting its significance as a therapeutic target in immuno-oncology and immunotherapy development.

Picture

FC

Flow cytometric analysis of human CD314 expression on Human PBMC (human peripheral blood mononuclear cells). Human PBMC were stained with Brilliant Violet 421™ Mouse Anti-Human CD3 Antibody and either FITC Mouse IgG1, k Isotype Control (left panel) or SDT FITC Mouse Anti-Human CD314 Antibody (right panel) at 5 μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.